What is the GRACE Score?
The GRACE (Global Registry of Acute Coronary Events) score is a validated clinical risk prediction tool used to estimate mortality risk in patients presenting with acute coronary syndrome (ACS). Developed from data collected from over 100,000 patients across 247 hospitals in 30 countries, the GRACE registry represents one of the largest and most diverse datasets in acute coronary care research.
The original GRACE risk model was published in 2003 and updated (GRACE 2.0) in 2014. It integrates eight clinical variables readily available at hospital presentation to generate a composite risk score. This score predicts both in-hospital mortality and mortality at 6 months and 1 year post-discharge, making it valuable for both immediate triage decisions and longer-term care planning.
The GRACE score is endorsed by the European Society of Cardiology (ESC) in its guidelines for the management of non-ST-elevation ACS and is widely used in emergency departments, coronary care units, and catheterization laboratories worldwide. Its primary role is to guide decisions about the intensity and timing of invasive management strategies, with higher-risk patients benefiting most from early invasive approaches including coronary angiography and percutaneous coronary intervention (PCI).
Types of Acute Coronary Syndrome
Acute coronary syndrome encompasses a spectrum of clinical presentations resulting from acute myocardial ischemia, typically caused by plaque rupture or erosion in a coronary artery with superimposed thrombosis:
- ST-Elevation Myocardial Infarction (STEMI): Complete coronary artery occlusion causing transmural ischemia, manifesting as persistent ST-segment elevation on ECG. Requires immediate reperfusion therapy (primary PCI or fibrinolysis) within defined time windows. The GRACE score can predict outcomes but does not change the management strategy of immediate reperfusion.
- Non-ST-Elevation Myocardial Infarction (NSTEMI): Partial or intermittent coronary occlusion with myocardial injury evidenced by elevated cardiac biomarkers (troponin) but without persistent ST elevation. The GRACE score is most impactful here, as it guides the timing and urgency of invasive strategy—early (within 24 hours) versus delayed (within 72 hours) catheterization.
- Unstable Angina (UA): Acute ischemic symptoms at rest or with minimal exertion, but without biomarker evidence of myocardial necrosis. The GRACE score helps differentiate patients who may benefit from invasive evaluation from those who can be safely managed conservatively.
Scoring Components Explained
The GRACE score incorporates eight variables that have been independently shown to predict mortality in ACS patients. Each captures a different aspect of the patient's clinical severity:
- Age: The most powerful predictor of ACS mortality. Older patients have less cardiac reserve, more comorbidities, and less ability to tolerate hemodynamic compromise. Points increase progressively with each decade.
- Heart Rate: Elevated heart rate reflects sympathetic activation, hemodynamic compromise, or heart failure. Very high rates (>150 bpm) are particularly ominous and may indicate cardiogenic shock or sustained arrhythmia.
- Systolic Blood Pressure: Lower blood pressure indicates worse cardiac function and hemodynamic instability. Paradoxically, very high blood pressure is associated with better outcomes (and thus receives fewer points), as it indicates preserved cardiac output.
- Serum Creatinine: Elevated creatinine reflects renal dysfunction, which is associated with worse ACS outcomes through multiple mechanisms: reduced drug clearance, more advanced atherosclerosis, volume overload, and limitations on contrast use during catheterization.
- Killip Class: Classifies the degree of heart failure at presentation, from Class I (no heart failure) to Class IV (cardiogenic shock). Higher Killip class indicates more extensive myocardial damage and worse prognosis.
- Cardiac Arrest at Admission: Cardiac arrest on presentation carries a substantial mortality risk and suggests a large area of myocardium at risk, significant arrhythmia burden, or both.
- ST-Segment Deviation: ST depression or elevation on the presenting ECG indicates active ischemia and is associated with larger infarct size and higher mortality.
- Elevated Cardiac Enzymes: Positive troponin or CK-MB confirms myocardial necrosis (infarction rather than unstable angina) and is associated with worse short-term and long-term outcomes.
Point Assignment Tables
| Age (years) | Points | Heart Rate (bpm) | Points |
|---|---|---|---|
| 30 – 39 | 0 | < 70 | 0 |
| 40 – 49 | 18 | 70 – 89 | 7 |
| 50 – 59 | 36 | 90 – 109 | 13 |
| 60 – 69 | 55 | 110 – 149 | 23 |
| 70 – 79 | 73 | 150 – 199 | 36 |
| 80 – 89 | 91 | ≥ 200 | 46 |
| ≥ 90 | 100 |
| Systolic BP (mmHg) | Points | Creatinine (mg/dL) | Points |
|---|---|---|---|
| < 80 | 40 | 0.0 – 0.39 | 1 |
| 80 – 99 | 37 | 0.4 – 0.79 | 3 |
| 100 – 119 | 30 | 0.8 – 1.19 | 5 |
| 120 – 139 | 22 | 1.2 – 1.59 | 7 |
| 140 – 159 | 18 | 1.6 – 1.99 | 9 |
| 160 – 199 | 10 | 2.0 – 3.99 | 15 |
| ≥ 200 | 0 | ≥ 4.0 | 20 |
| Variable | If Present, Points Added |
|---|---|
| Killip Class II | +20 |
| Killip Class III | +39 |
| Killip Class IV | +59 |
| Cardiac Arrest at Admission | +39 |
| ST-Segment Deviation | +28 |
| Elevated Cardiac Enzymes | +14 |
Risk Stratification
| GRACE Score | Risk Category | In-Hospital Mortality | 6-Month Mortality |
|---|---|---|---|
| ≤ 108 | Low | < 1% | < 3% |
| 109 – 140 | Intermediate | 1 – 3% | 3 – 8% |
| > 140 | High | > 3% | > 8% |
Patients in the high-risk category benefit most from an early invasive strategy (catheterization within 24 hours). Intermediate-risk patients should generally undergo invasive evaluation within 72 hours. Low-risk patients may be suitable for either a conservative or selectively invasive approach, guided by additional clinical factors including recurrent symptoms, dynamic ECG changes, or provocable ischemia on stress testing.
Clinical Decision-Making
The GRACE score directly influences several key management decisions in the acute care setting:
- Timing of invasive strategy: ESC guidelines recommend that very high-risk NSTEMI patients (GRACE > 140) undergo coronary angiography within 24 hours, while intermediate-risk patients can be evaluated within 72 hours.
- Intensity of antithrombotic therapy: Higher-risk patients are more likely to benefit from potent antiplatelet agents (prasugrel, ticagrelor) and may warrant glycoprotein IIb/IIIa inhibitor therapy during PCI.
- Level of monitoring: High GRACE scores warrant coronary care unit admission with continuous telemetry monitoring, while low-risk patients may be safely managed on step-down units.
- Post-discharge care planning: The GRACE score at discharge helps identify patients who need more intensive follow-up, aggressive secondary prevention, and possibly cardiac rehabilitation referral.
- Patient communication: The score provides an objective framework for discussing risk with patients and families, aiding in shared decision-making about invasive procedures and long-term treatment goals.
GRACE vs. TIMI Score
The TIMI (Thrombolysis in Myocardial Infarction) risk score is the other widely used ACS risk tool. While both are validated and clinically useful, they differ in several important ways:
| Feature | GRACE | TIMI |
|---|---|---|
| Variables | 8 continuous/categorical | 7 binary (yes/no) |
| Derivation cohort | Multinational registry (n > 100,000) | Clinical trial data |
| Predicted outcome | In-hospital and 6-month mortality | 14-day composite events |
| Discrimination (c-statistic) | 0.83 – 0.85 | 0.65 – 0.75 |
| Ease of use | Requires calculator | Simple bedside calculation |
| Guideline endorsement | ESC (primary recommendation) | AHA/ACC (commonly used) |
The GRACE score generally provides superior discriminative ability (higher c-statistic) compared to the TIMI score, particularly for predicting mortality. However, the TIMI score's simplicity makes it popular for bedside assessment. Many clinicians use both scores complementarily, with the GRACE score providing more precise risk quantification when available.
Limitations
- Static assessment: The GRACE score captures risk at a single time point and does not account for dynamic changes in the patient's clinical trajectory, response to initial therapy, or procedural complications.
- Simplified scoring: The simplified point-based system used in clinical practice is an approximation of the original logistic regression model, which may lose some precision at the extremes of the score range.
- Population representation: While derived from a large multinational registry, the GRACE cohort may not perfectly represent all patient populations, particularly those underrepresented in the original study (e.g., very young patients, certain ethnic groups).
- Evolving treatments: As ACS management evolves with new interventions, medications, and care protocols, the absolute risk estimates associated with specific GRACE scores may shift, even if the relative risk ranking remains valid.
- Missing variables: The score does not incorporate some prognostically important factors such as left ventricular function, coronary anatomy, diabetes, or frailty, which may provide additional risk information.
Frequently Asked Questions
When should the GRACE score be calculated?
The GRACE score should be calculated as soon as possible upon presentation with suspected ACS, ideally within the first few hours. It requires vital signs, an ECG, basic blood work (creatinine), and cardiac biomarkers (troponin). For NSTEMI/UA patients, it directly guides the urgency of invasive management. For STEMI patients, while the score is prognostically useful, it does not change the primary management strategy of immediate reperfusion.
Can the GRACE score be recalculated during hospitalization?
Yes, and this is recommended. The GRACE discharge score uses slightly different variables to predict post-discharge mortality and can help guide the intensity of outpatient follow-up and secondary prevention efforts. Dynamic reassessment is particularly valuable in patients whose clinical status changes significantly during hospitalization.
What does a GRACE score of 0 mean?
A GRACE score of exactly 0 is extremely unlikely in practice because even young patients with normal vital signs will accumulate some points from the blood pressure and creatinine components. A very low score (under 60–70) indicates low risk, but clinical judgment should always complement the numerical score.
Is the GRACE score applicable to all chest pain patients?
The GRACE score was specifically developed and validated for patients with confirmed or strongly suspected ACS. It should not be applied to patients with clearly non-cardiac chest pain, stable angina without acute changes, or chest pain from other causes such as pulmonary embolism, aortic dissection, or musculoskeletal conditions. Applying the score outside its intended population may produce misleading results.
How does GRACE 2.0 differ from the original GRACE score?
GRACE 2.0, published in 2014, refined the original model using updated statistical methods and extended follow-up data. It provides more accurate risk estimates, particularly for 1-year and 3-year mortality prediction. It also allows calculation when one or two variables are missing by using multiple imputation techniques. The core variables remain the same, but the mathematical model underlying the risk calculation is more sophisticated.
Should treatment decisions be based solely on the GRACE score?
No. The GRACE score is a decision-support tool, not a decision-making replacement. It should be integrated with the full clinical picture, including patient preferences, comorbidities, bleeding risk (assessed by tools like the CRUSADE score), coronary anatomy, left ventricular function, and the treating team's clinical judgment. It provides a standardized framework for risk communication but should never override sound clinical reasoning.